Read More Pharma Industry News Lexeo’s second cardiac gene therapy gains FDA support ahead of year-end update LX2020 gains FDA RMAT status after early heart gene therapy data, strengthening Lexeo’s regulatory path ahead of a key 12-month update. bySoujanya RaviAugust 8, 2026